secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001100682-26-000020
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Labs Q4 revenue $994M, GAAP loss $5.62; sees 2026 non-GAAP EPS $10.70-$11.20
--------------------------------------------------------------------------------

- Q4 GAAP loss per share $(5.62) from $994.2M revenue (-0.8% YoY); non-GAAP EPS $2.39 (-10.2%).
- FY2025 revenue $4.02B (-0.9%); GAAP loss $(2.91)/share; non-GAAP EPS $10.28 (-0.4% vs $10.32).
- DSA organic revenue -3.3% in Q4; CEO cites robust DSA net bookings and cautious optimism for demand recovery.
- 2026 organic revenue guidance (1.0)% to flat; non-GAAP EPS $10.70-$11.20 implies 4-9% growth.
- Recorded $211M intangible and $165M goodwill impairments in Biologics Solutions (Manufacturing segment).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068226000020/0001100682-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068226000020/crl-20260218.htm
  HTML page:      https://secwatch.observer/filing/0001100682-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer